Cipla net profit rises 7 percent to Rs 808 crore in Q3
New Delhi: Drug major Cipla on Wednesday reported a 7 percent increase in its consolidated net profit to Rs 808 crore for the third quarter ended December 2022, aided by robust sales.
The Mumbai-based drug maker had reported a net profit of Rs 757 crore for the October-December period of the last fiscal.
Its total revenue from operations rose to Rs 5,810 crore for the third quarter compared to Rs 5,479 in the year-ago period, Cipla said in a regulatory filing.
For the nine months ended December 31, 2022, the company reported a net profit of Rs 2,311 crore against Rs 2,176 crore in the same period last fiscal.
Read also: Cipla expects elevated capital expenditure on automation to continue for three more years
Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. The Company was founded by Khwaja Abdul Hamied in 1935 in Mumbai.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.